PPT-SOF/VEL

Author : lois-ondreau | Published Date : 2016-09-10

400100 mg qd N 500 N 100 W12 Placebo gt 18 years Chronic HCV infection Genotype 1 2 4 5 or 6 Naïve or pretreatment with IFNbased regimen Compensated cirrhosis

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "SOF/VEL" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

SOF/VEL: Transcript

400100 mg qd N 500 N 100 W12 Placebo gt 18 years Chronic HCV infection Genotype 1 2 4 5 or 6 Naïve or pretreatment with IFNbased regimen Compensated cirrhosis allowed No HBV or HIV coinfection. Acquisition Perspective . to. . NDIA. James W. Cluck. Acquisition Executive &. Director, Center for . Acquisition and . Logistics (SOAL. ). 20 March 2009. Agenda. Mission. SOF Acquisition. Special Operations Peculiar. Placebo. LDV/SOF + placebo. Randomisation*. 1 : 1. Double-blind. SIRIUS . Study. : LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior PI therapy. Design. W24. W12. ≥ 18 years. Chronic HCV infection. Versatile . Efficient. . and. . Longer. Wagon . for. European Transportation. Dipl.-Ing. A. Carrillo Zanuy. EC FP7-SST-2010-RTD-1. Collaborative Project, Nr. 265610. Duration: 25 M . (01.12.2010-31.12.2012). With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: . Interim Results of a European Multicenter Compassionate Use Program. Herzer K,. 1. . Welzel. . 400/100/100 mg QD. N = 501. N = 440. W8. SOF/VEL 400/100 mg QD. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. Treatment-naïve or . IFN-experienced. Compensated cirrhosis **. allowed . qd. + SOF 400 mg . qd. N = 40. W12. 18-70 years. Chronic HCV infection. Genotype 4. HCV RNA > 10 000 IU/ml. Naïve or pre-treatment. with PEG-IFN + RBV. Compensated cirrhosis allowed. No HBV or HIV co-infection. With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: . Interim Results of a European Multicenter Compassionate Use Program. Herzer K,. 1. . Welzel. . in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label. BOSON . Study. : SOF + RBV . +. PEG-IFN . for genotypes 2 and 3. ≥ 18 years. Chronic HCV infection. Genotype 2, treatment-experienced with cirrhosis. . and. . Longer. Wagon . for. European Transportation. Dipl.-Ing. A. Carrillo Zanuy. EC FP7-SST-2010-RTD-1. Collaborative Project, Nr. 265610. Duration: 25 M . (01.12.2010-31.12.2012). 4 Partners: . 12. (HCV RNA < 25 IU/ml), . with. 95% CI. DCV 60 mg . qd. SOF 400 mg . qd. DCV 60 mg . qd. SOF 400 mg . qd. Not randomised. Open. -label. ALLY-3 . Study. : DCV SOF for HCV genotype 3. W12. for 12 weeks in liver transplant recipients with genotype 1-4. Agarwal K. J . Hepatol. . 2018;69:603-7. SOF/VEL: 400/100 mg 1 . tablet. QD. Liver transplant recipients. Recurrent HCV infection after transplantation. ≥ 18 years. Chronic HCV infection. Genotype 1 or 4. HCV RNA > 10 000 IU/ml. Treatment-naïve or pre-treated. w. ith PEG-IFN ± RBV. Cirrhosis (> 14.5 . kPa. on . FibroScan. ). Portal hypertension or liver . April 10. –14. , 2019. Vienna, Austria. Disclaimer. These non-promotional slides are intended to be used as educational material only in response to an unsolicited question or request. The double-dagger (.

Download Document

Here is the link to download the presentation.
"SOF/VEL"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.